Inflammation, autoimmunity and ovarian cancer
炎症、自身免疫和卵巢癌
基本信息
- 批准号:8621880
- 负责人:
- 金额:$ 6.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-09 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAnimal ModelAntibodiesAntigensAutoantibodiesAutoimmune DiseasesAutoimmunityCellsCessation of lifeDataDevelopmentDiagnosticEmployee StrikesEngineeringEnvironmentEtiologyEventFDA approvedGenerationsHumanImmuneImmunityImmunosuppressive AgentsIncidenceInfiltrationInflammationInflammatoryKnowledgeLinkLogisticsLymphocyteLymphocyte CountMalignant NeoplasmsMalignant neoplasm of ovaryModelingMultiple SclerosisOutcome StudyOvarianOvaryPharmaceutical PreparationsPhysiologyPilot ProjectsPreventionRoleSerumSurrogate EndpointTestingTumor AntibodiesTumor AntigensUnited StatesWomanangiogenesisdisorder controleggimprovedinsightmesothelinmiddle agemortalitypreventpublic health relevanceselenium binding proteinselenium-binding proteinstraffickingtumor
项目摘要
DESCRIPTION (provided by applicant): The laying hen is an emerging animal model of spontaneous ovarian cancer (OVCA). This model addresses a gap between studies of spontaneous human OVCA and non-spontaneous, engineered models of OVCA. Evidence suggests the hen can provide needed information on early events related to the role of inflammation and autoimmunity in the etiology of OVCA since humans and hens have striking similarities in ovarian physiology, anti-ovarian autoantibodies (AOA), anti-tumor antibodies and OVCA and immune cell trafficking into tumors. Interestingly, ovarian autoimmunity and AOA are associated similarly with prematurely decreased ovarian function in middle aged women and hens. We showed that both hen and human OVCA are associated with AOA and with antibodies to the same tumor antigens (e.g., mesothelin (MSLN), Selenium Binding Protein 1 (SBP1) and p53. In a pilot study, hens with normal ovaries but low egg laying (i.e., reduced ovarian function)
with AOA developed OVCA within 10 months suggesting that autoimmunity could precede or predict OVCA. The concept that autoimmunity is linked to cancer is not new. However, the potential progression of autoimmunity to OVCA has been minimally explored given the logistics of carrying out such studies in humans. The relationship among autoantibodies, inflammation and spontaneous tumor development can easily be tested in hens. In this study we will use the laying hen model of OVCA to determine (Aim 1) whether serum autoantibodies to specific antigens such as anti-mesothelin (MSLN), anti-p53 and/or anti-selenium binding protein 1 (SBP1) predict OVCA, if antibodies are correlated with increased lymphocyte numbers in the ovary and if these changes in immunity are more often associated with a pro-inflammatory environment in the ovary, and (Aim 2) confirm that FTY720 (fingolimod; an S1P agonist that is FDA approved for amelioration of the autoimmune disease, multiple sclerosis) reverses lymphocyte infiltration and inflammation and improves ovarian function and that this is associated with a decrease in a surrogate endpoint (angiogenesis) for OVCA incidence. Accomplishment of these Aims will provide further evidence for antibodies as markers for OVCA and for reduction of OVCA by an immunosuppressant. This will contribute to knowledge of a mechanism involved in OVCA generation that can be targeted to prevent or control OVCA.
描述(由申请人提供):蛋鸡是一种新兴的自发性卵巢癌(OVCA)动物模型。该模型解决了自发的人类OVCA和非自发的OVCA工程模型之间的研究差距。有证据表明,由于人类和母鸡在卵巢生理、抗卵巢自身抗体(AOA)、抗肿瘤抗体、OVCA和免疫细胞转运到肿瘤中具有惊人的相似性,母鸡可以提供与OVCA病因中炎症和自身免疫作用相关的早期事件所需的信息。有趣的是,卵巢自身免疫和AOA与中年妇女和母鸡卵巢功能过早下降相似。我们发现母鸡和人类的OVCA都与AOA和针对相同肿瘤抗原(如间皮素(MSLN)、硒结合蛋白1 (SBP1)和p53)的抗体相关。在一项初步研究中,卵巢正常但产蛋率低(即卵巢功能下降)的母鸡
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JUDITH L LUBORSKY其他文献
JUDITH L LUBORSKY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JUDITH L LUBORSKY', 18)}}的其他基金
Protein targets of ovarian and oocyte autoantibodies
卵巢和卵母细胞自身抗体的蛋白质靶点
- 批准号:
6626663 - 财政年份:2003
- 资助金额:
$ 6.83万 - 项目类别:
Protein targets of ovarian and oocyte autoantibodies
卵巢和卵母细胞自身抗体的蛋白质靶点
- 批准号:
7191745 - 财政年份:2003
- 资助金额:
$ 6.83万 - 项目类别:
Protein targets of ovarian and oocyte autoantibodies
卵巢和卵母细胞自身抗体的蛋白质靶点
- 批准号:
6847781 - 财政年份:2003
- 资助金额:
$ 6.83万 - 项目类别:
Protein targets of ovarian and oocyte autoantibodies
卵巢和卵母细胞自身抗体的蛋白质靶点
- 批准号:
6710186 - 财政年份:2003
- 资助金额:
$ 6.83万 - 项目类别:
Protein targets of ovarian and oocyte autoantibodies
卵巢和卵母细胞自身抗体的蛋白质靶点
- 批准号:
7026419 - 财政年份:2003
- 资助金额:
$ 6.83万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 6.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 6.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 6.83万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 6.83万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 6.83万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 6.83万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 6.83万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 6.83万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 6.83万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 6.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)